KNSA Q3 2023 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena

KNSAKiniksa Pharmaceuticals, Ltd.

$3B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$67M-32.4% YoY

Gross Profit

$40M59.1% margin

Operating Income

-$11M-16.3% margin

Net Income

-$14M-20.7% margin

EPS (Diluted)

$-0.20

QoQ Revenue Growth

-6.2%

Cash Flow

Operating Cash Flow

$17M

Free Cash Flow

$17M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$483M

Total Liabilities

$78M

Stockholders' Equity

$405M

Cash & Equivalents

$118M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$67M	$99M	-32.4%
Gross Profit	$40M	$87M	-54.2%
Operating Income	-$11M	$46M	-123.5%
Net Income	-$14M	$224M	-106.2%

Revenue Segments

Product

$65M97%

Collaboration

$2M3%